Lily K Stern MD

@ucsfalumni | @CedarsSinai Advanced Heart Disease & Transplant, cardiac amyloidosis | Singer-songwriter in a former life | Tweets my own

[Lily K Stern MD @LilySternMD]

1/ Check out our recent publication in @JCardFail !

The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology - https://t.co/mYuUeD3Ms7

[Lily K Stern MD @LilySternMD]

Hot off the press from CARS (Cardiac Amyloid Registry Study)!

👏👏👏 to Isabel Wees & @JLGrodin for leading this work!

[Munir S Janmohamed MD FACC, FHFSA @MunirJanmohamed]

🔥 New in @JACCJournals #HF
❓prognostic role of p.V142I on race, genotype and outcomes in ATTR-CA

🔑 Black patients experienced a more advanced ATTR-CA phenotype irrespective of genotype

🔗https://t.co/kpw2idBv5J

[Ahmad Masri @MasriAhmadMD]

Transthyretin amyloid cardiomyopathy characteristics have changed over the past 20 years. However, significant residual mortality still represents a significant unmet need.

https://t.co/hLPyjN94LS
#cardiotwitter

[Ronald Witteles @Ron_Witteles]

(1/14) 🚨I had the privilege of providing commentary on the Phase 2 #coramitug trial at #AHA25. The headline was that patients who received high-dose (60 mg/kg) coramitug had significant reductions in NT-proBNP at 1 year compared with placebo. So it’s an unequivocal win, right? The full story is a bit more complicated…🤔

[Ronald Witteles @Ron_Witteles]

More incredible #CRISPR data with #Nexz published today in @NEJM -- this time 2 year data from the Phase 1 #ATTR polyneuropathy study. #TTR levels down 90% by day 28... and 92% at month 24! Improved neuropathy functionally and by #Nfl levels. Exciting prospects for #MAGNITUDE. https://t.co/2tMKXtXx7B

[Ahmad Masri @MasriAhmadMD]

1/2 We presented exploratory data from ATTRibute-CM looking at all events - CVM and recurrent CVH - which show early and sustained effect of acoramidis throughout the study.

#HFSA2025
#CardioTwitter
#MedIQHFSA2025

[Brett Sperry, MD @BrettSperryMD]

Sharing our research on slowed worsening of conduction disease with acoramidis

Great session with multiple leaders in the field and great discussions!

[Emily Margolin, MD @EmilyMargolinMD]

Proud to share our review on transthyretin amyloid cardiomyopathy! https://t.co/giACwEptSR

We break down the current treatments, what’s in the pipeline, and what’s next.

@UreyTony @UCSDCardiology

[Ruey Hu, MD, MPH @ruey_hu]

When people talk about "telemonitoring" in heart failure, they can be talking about very different things.

Great teamwork on this systematic review by @KwaahPatrick @barbiemalaga @kassemfarhatMD @AAbdullah780 @EOlumuyideMD and collaboration with @MHBeasleyMD
@LilySternMD @adrianjdasilva @slumberbell in @MdpiMedicina https://t.co/SvBWD57ADW

[Yosef Manla, MD, FESC @ManlaYosef]

Presented this at #ISHLT2025: In our single-center study @SmidtHeart , pre- heart transplant sensitization & older donor age were associated with immediate presentation of severe PGD-LV ⚠️.
Immediate presentation = worse 30-day & 1-yr survival vs delayed presentation 📉.@ISHLT

[Lily K Stern MD @LilySternMD]

Thank you so much for tuning in!

[Eugenio Cingolani, MD @EugenioCingolan]

Great #Medicine #GR by Dr. Lily Stern @LilySternMD #Cardiology @SmidtHeart ➡️ #Amyloid #CardiacAmyloid ⏩⏩ #Diagosis #NovelTherapeutics #Use of #AI 🖥️ based algorithms for diagnosis !
@SmidtHeart @CedarsSinaiMed @CMECedarsSinai @David_Ouyang #AdvancedHF #ECG #LowVoltage ⚡️

[Lily K Stern MD @LilySternMD]

Thank you @ACCinTouch and @AmiBhattMD for hosting a great discussion and highlighting our research!

@David_Ouyang @amey_vrudhula @SmidtHeart @CedarsSinaiMed @Ron_Witteles @Paul_P_Cheng

[American College of Cardiology @ACCinTouch]

ACC CardiaCast: Innovation in Action: 🆕 Podcast Series

ACC Chief Innovation Officer @AmiBhattMD is joined by Drs. @amey_vrudhula & @LilySternMD to delve into AI model training & how to leverage AI for early 🔎 of cardiac amyloidosis.

🎧 https://t.co/gWmPaExZMB #ACCInnovation

[Yosef Manla, MD, FESC @ManlaYosef]

I am excited to share our recent publication @TheJHLT, demonstrating how therapeutic plasma exchange improves survival in patients experiencing severe primary graft dysfunction after heart transplantation.
Link: https://t.co/prdAxs9N0Z
Beyond grateful to my mentor, Dr.Kobashigawa, and the team @SmidtHeart for the support and guidance

[Ronald Witteles @Ron_Witteles]

🚨🚨🚨 MAJOR news in the #amyloidosis world this morning with positive topline results of #HELIOS-B. #Vutrisiran met all primary & secondary endpoints. Let's break down what we know... #StanfordAmyloidCenter (1/13)

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

When the #womenincardiology get together in #SoCal, it is the best! @CaliforniaACC @JanetWeiMD @netta_doc (missing because of 🦷) Male Allies always welcome like the amazing @datsunian (with future #WIC)

@LilySternMD @USC_Cardiology @SmidtHeart

[David Ouyang, MD @David_Ouyang]

Second first author research publication by star @SarnoffCardio fellow and soon to be @StanfordMedRes @amey_vrudhula!

@LilySternMD @Paul_P_Cheng @pieroricchiuto @Ron_Witteles @JigPatelMDPhD

[David Ouyang, MD @David_Ouyang]

Working with expert clinicians like @LilySternMD and @JigPatelMDPhD here at @SmidtHeart and similar amyloid specialists at the four sites, we are focused on bringing the right diagnoses to the right patients, and use AI facilitate timely and effective care.

https://t.co/K3dGIS1vSP

[Lily K Stern MD @LilySternMD]

@chimoose @CedarsSinai Thank you for bringing up this memory 😊
@seantiwanak

[Lily K Stern MD @LilySternMD]

4/ @robmentz @ParagGoyalMD @CedarsSinaiMed @SmidtHeart

[Lily K Stern MD @LilySternMD]

1/ Check out our recent publication in @JCardFail !

The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology - https://t.co/mYuUeD3Ms7

[Lily K Stern MD @LilySternMD]

3/
@JLGrodin @MathewMaurer @FrederickRuberg @MandarArasMD @docbhardwaj @YevgeniyBr @philimd @HannaGaggin @JanMGriffin @joshmitchellmd @SumeetMitter @RajeevCMohan @HanniaRamosMD @ReyentovichHFMD @BrettSperryMD @SpencerCarter55 @UreyTony @MKittlesonMD @JigPatelMDPhD